Cellectar to Participate at Upcoming Institutional Investor Conferences
Cellectar Biosciences (NASDAQ: CLRB) announced participation in upcoming conferences for 1x1 meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB) announced participation in upcoming conferences for 1x1 meetings. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, and the Roth Capital Partners 33rd Annual Conference from March 15-17, 2021. Interested parties can schedule meetings through provided links. Cellectar focuses on developing cancer-targeting drugs using its Phospholipid Drug Conjugate™ (PDC) platform, including its lead product CLR 131, currently in pivotal trials for various cancers.
Details
News Market Reaction – CLRB
The recorded move for CLRB in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will be available for 1x1 meetings at the following upcoming conferences:
| H.C. Wainwright Global Life Sciences Conference | |
| Date: | March 9-10, 2021 |
| Time: | Available for 1x1 meetings |
| To schedule, click on the link HERE | |
| Roth Capital Partners 33rd Annual Conference | |
| Date: | March 15-17, 2021 |
| Time: | Available for 1x1 meetings |
| To schedule, click on the link HERE | |
The company’s presentation is available for on-demand viewing in the link HERE.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia, a Phase 2b study in r/r multiple myeloma patients, the CLOVER-2 Phase 1 study for a variety of pediatric cancers, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.